Timothy Rolph - 16 Jun 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
16 Jun 2023
Net transactions value
-$4,259,666
Form type
4
Filing time
21 Jun 2023, 17:46:35 UTC
Previous filing
15 Jun 2023
Next filing
25 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $24,400 +40,000 +21% $0.6100* 229,420 16 Jun 2023 Direct
transaction AKRO Common Stock Sale $2,691,912 -49,325 -21% $54.58 180,095 16 Jun 2023 Direct F1
transaction AKRO Common Stock Sale $1,512,607 -27,462 -15% $55.08 152,633 16 Jun 2023 Direct F2
transaction AKRO Common Stock Sale $79,547 -1,413 -0.93% $56.30 151,220 16 Jun 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -40,000 -93% $0.000000 2,796 16 Jun 2023 Common Stock 40,000 $0.6100 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.935, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $56.03 to $56.45, inclusive.
F4 The options are vested and currently exercisable.